Analyst Sara Nik of H.C. Wainwright reiterated a Buy rating on Cidara Therapeutics, retaining the price target of $150.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sara Nik’s rating is based on the promising clinical data from Cidara Therapeutics’ CD388, a non-vaccine candidate for preventing influenza. The recent Phase 2b clinical trial results presented during ID Week 2025 demonstrated that CD388 met its primary endpoint of preventive efficacy, showing significant protection against symptomatic influenza with a single subcutaneous dose. The updated data provided deeper insights into the drug’s efficacy, pharmacokinetics, and safety, which further validate the dose selection for the ongoing Phase 3 ANCHOR study.
Sara Nik emphasizes the importance of the detailed virology breakdown and the dose-dependent increase in preventive efficacy, particularly against influenza A. These findings support the continued development of CD388, especially for high-risk groups such as those with immune-compromised conditions or co-morbidities. The comprehensive safety profile and the mechanistic support from pharmacokinetic data further bolster confidence in CD388’s potential as a preventive treatment, justifying the Buy rating.
In another report released on October 16, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $190.00 price target.